Business Description
StemCell Institute
ISIN : JP3399640006
Total Employee Number:
227Description
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.98 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | 1.25 | |||||
Interest Coverage | 37.2 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.68 | |||||
Beneish M-Score | -2.11 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.9 | |||||
3-Year EBITDA Growth Rate | -1.4 | |||||
3-Year EPS without NRI Growth Rate | -9.5 | |||||
3-Year Book Growth Rate | 5.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 87.83 | |||||
9-Day RSI | 81.35 | |||||
14-Day RSI | 73.78 | |||||
3-1 Month Momentum % | -12.23 | |||||
6-1 Month Momentum % | -20.77 | |||||
12-1 Month Momentum % | -30.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.17 | |||||
Quick Ratio | 1.16 | |||||
Cash Ratio | 0.63 | |||||
Days Inventory | 18.03 | |||||
Days Sales Outstanding | 270.66 | |||||
Days Payable | 24.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.6 | |||||
Shareholder Yield % | 2.79 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 60.9 | |||||
Operating Margin % | 7.21 | |||||
Net Margin % | 5.55 | |||||
EBITDA Margin % | 13.52 | |||||
FCF Margin % | -16.12 | |||||
OCF Margin % | 2.61 | |||||
ROE % | 5.91 | |||||
ROA % | 1.99 | |||||
ROIC % | 1.81 | |||||
3-Year ROIIC % | -3.35 | |||||
ROC (Joel Greenblatt) % | 18.14 | |||||
ROCE % | 6.5 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 49.76 | |||||
PE Ratio without NRI | 49.83 | |||||
PEG Ratio | 1.87 | |||||
PS Ratio | 2.76 | |||||
PB Ratio | 2.88 | |||||
Price-to-Tangible-Book | 3.15 | |||||
Price-to-Operating-Cash-Flow | 105.48 | |||||
EV-to-EBIT | 24.07 | |||||
EV-to-EBITDA | 14.14 | |||||
EV-to-Revenue | 1.91 | |||||
EV-to-FCF | -11.85 | |||||
Price-to-GF-Value | 0.42 | |||||
Price-to-Projected-FCF | 2.75 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.99 | |||||
Price-to-Graham-Number | 2.64 | |||||
Earnings Yield (Greenblatt) % | 4.15 | |||||
FCF Yield % | -5.86 | |||||
Forward Rate of Return (Yacktman) % | 19.37 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
StemCell Institute Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 2,811.344 | ||
| EPS (TTM) (円) | 15.433 | ||
| Beta | 0.2604 | ||
| 3-Year Sharpe Ratio | -1.32 | ||
| 3-Year Sortino Ratio | -1.44 | ||
| Volatility % | 30.37 | ||
| 14-Day RSI | 73.78 | ||
| 14-Day ATR (円) | 17.765658 | ||
| 20-Day SMA (円) | 713.25 | ||
| 12-1 Month Momentum % | -30.08 | ||
| 52-Week Range (円) | 627 - 1245 | ||
| Shares Outstanding (Mil) | 10.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
StemCell Institute Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
StemCell Institute Stock Events
| Event | Date | Price (円) | ||
|---|---|---|---|---|
| JPY 25.000000 Cash Dividend | 2024-09-27 | 1,654.00 (-1.37%) | ||
| 2:1 Stock Split | 2022-12-29 | 2,585.00 (+2.78%) |
Show
Entries
StemCell Institute Frequently Asked Questions
What is StemCell Institute(TSE:7096)'s stock price today?
The current price of TSE:7096 is 円768.00. The 52 week high of TSE:7096 is 円1245.00 and 52 week low is 円627.00.
When is next earnings date of StemCell Institute(TSE:7096)?
The next earnings date of StemCell Institute(TSE:7096) is .
Does StemCell Institute(TSE:7096) pay dividends? If so, how much?
StemCell Institute(TSE:7096) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on StemCell Institute
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers